Latest news
Watch: Amprologix CSO Mat Upton on the first in a new class of antibiotics
Amprologix Chief Scientific Officer Mat Upton discusses the company’s recent fund raising raising, plans for a Series A round and the future of its novel antibiotics to tackle resistant diseases.
Read moreAmprologix raises £740,000 in pre-Series A funding round
Portfolio company raises money to accelerate development of antibiotics to combat antimicrobial resistant MRSA and other diseases. Its lead candidate epidermicin NI01 is the first in a new class of antibiotics.
Read moreWatch: Dekiln hits milestone with first commercial installation
Dekiln has completed the first commercial installation of Eralith, moved into new, larger premises to scale up, and won support from the Henry Royce Institute. Watch to learn more.
Read moreOur portfolio
Our portfolio companies are involved in developing a wide range of technologies based on cutting-edge intellectual property to meet the needs and demands of the world.
See all companiesDekiln
Dekiln, formerly known as DeakinBio, has developed BioSintering®, a technology combining waste materials such as gypsum powder with bio-based active ingredients to produce a revolutionary, low-carbon alternative to traditional ceramic tiles.
Learn moreShare price
Share Price InformationLatest downloads
Half Year Results 2024/25
